Innovations in Malaria Vaccines and Biologics Development (IMVB)

The purpose is to support the efforts of the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP) to develop malaria vaccines or monoclonal antibodies (mAbs) that reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum.

The Innovations in Malaria Vaccine and Biologics (IMVB) activity is a part of the MVDP portfolio that will support strategic research of new or improved malaria vaccines that target the pre-erythrocytic and/or erythrocytic stages of the parasite life cycle that will include prototype vaccine development, preclinical studies, and/or early clinical studies of promising vaccine candidates that offer improvements in efficacy, durability, and affordability over the currently WHO-recommended vaccines, with hopes of meeting the World Health Organization’s (WHO) Preferred Product Characteristics (PPCs) for malaria vaccines. The activity may also support research on mAbs for use in development of improved malaria vaccines and passive protection against malaria.